# US 2013/0253049 A1 · Treatment for pulmonary hypertension

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0253049 A1
- Document ID: US20130253049A1
- Status: Published application
- Kind: A1
- Application number: 13/899,734
- Filed: 2013-05-22
- Published: 2013-09-26
- Earliest claimed: 2010-03-15
- Assignees: United Therapeutics Corporation
- Applicants: United Therapeutics Corporation
- Inventors: Martine A. Rothblatt; Lewis J. Rubin
- Web page: https://patentgrep.com/patent/US20130253049A1

## CPC

- A61K 31/5585: having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 31/557: Eicosanoids, e.g. leukotrienes {or prostaglandins}
- A61K 31/5575: having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A61K 31/5578: having a pentalene ring system, e.g. carbacyclin, iloprost
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

One embodiment relates to a method of treating pulmonary hypertension based upon co-administering to a subject in need thereof a pharmaceutically effective amount of an oral therapeutic agent for treating pulmonary hypertension and a pharmaceutically effective amount of an inhaled therapeutic agent for treating pulmonary hypertension. The benefit of the co-administration of these agents is to eliminate or reduce one or more side effects associated with mono-therapy of either agent, as well as one or more side effects associated with other administration routes such as subcutaneous or intravenous administration.

## Claims

### Claim 1

A method of treating pulmonary hypertension comprising co-administering to a subject in need thereof a pharmaceutically effective amount of an oral therapeutic agent for treating pulmonary hypertension and a pharmaceutically effective amount of an inhaled therapeutic agent for treating pulmonary hypertension, wherein the oral therapeutic agent comprises beraprost or a pharmaceutically acceptable salt thereof and the inhaled therapeutic agent comprises treprostinil or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject is a human being.

### Claim 3 (depends on 1)

The method of claim 1, wherein the inhaled therapeutic agent comprises sodium salt of treprostinil.

### Claim 4 (depends on 1)

The method of claim 1, wherein the co-administration delays the time to initiation of parenteral therapy for pulmonary hypertension in comparison to therapy with either an oral or inhaled therapeutic agent for pulmonary hypertension used alone.

### Claim 5

A method of reducing a side effect of a pulmonary hypertension treatment administered by subcutaneous or intravenous delivery, comprising co-administering to a subject in need thereof a pharmaceutically effective amount of an oral therapeutic agent for treating pulmonary hypertension and a pharmaceutically effective amount of an inhaled therapeutic agent for treating pulmonary hypertension, wherein the oral therapeutic agent comprises beraprost or a pharmaceutically acceptable salt thereof and the inhaled therapeutic agent comprises treprostinil or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 5)

The method of claim 5, wherein the subject is a human being.

### Claim 7 (depends on 5)

The method of claim 5, wherein the inhaled therapeutic agent comprises sodium salt of treprostinil.

### Claim 8 (depends on 5)

The method of claim 5, wherein the side effect comprises systemic hypotension, infection, thrombosis, site infusion pain, sudden infusion interruption resulting in death, leg pain, or combinations thereof.
